UCLA Chest Pain and Unstable Angina

APPRAISE-2 Apixaban 5mg bd or placebo 6 months 7392 patients with recent STEMI or NSTEMI ACS + two additional risk factors for IHD TIMI major bleeding 19% aspirin. 81% aspirin + thienopyridine Trial terminated early due to an excess of bleeding events. Bleeding rate was 1.3% in the apixaban group vs 0.35% in placebo group (HR 2.59, p=0.001) ................
................